These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Fibrinolytic agents: mechanisms of activity and pharmacology. Lijnen HR; Collen D Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491 [TBL] [Abstract][Full Text] [Related]
5. [Staphylokinase and its mutants: a new generation of thrombolytic agents]. Lebrazi J; Elalamy I; Helft G; Samama MM J Mal Vasc; 1998 Apr; 23(2):92-8. PubMed ID: 9608920 [TBL] [Abstract][Full Text] [Related]
6. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Collen D; De Cock F; Stassen JM Circulation; 1993 Mar; 87(3):996-1006. PubMed ID: 8443918 [TBL] [Abstract][Full Text] [Related]
7. Kinetic properties of the activator complexes plasmin--staphylokinase and plasmin(ogen)--streptokinase in vitro. Sazonova IY; Aisina RB; Muhametova LI; Varfolomeyev SD Biochemistry (Mosc); 1999 Jan; 64(1):66-74. PubMed ID: 9986915 [TBL] [Abstract][Full Text] [Related]
8. [Staphylokinase for a better thrombolytic treatment of heart and platelet diseases]. Vanderschueren S Verh K Acad Geneeskd Belg; 2000; 62(1):69-75. PubMed ID: 10769618 [TBL] [Abstract][Full Text] [Related]
9. Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion. Nedaeinia R; Faraji H; Javanmard SH; Ferns GA; Ghayour-Mobarhan M; Goli M; Mashkani B; Nedaeinia M; Haghighi MHH; Ranjbar M Mol Biol Rep; 2020 Jan; 47(1):819-841. PubMed ID: 31677034 [TBL] [Abstract][Full Text] [Related]
10. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis. Lijnen HR; Stassen JM; Vanlinthout I; Fukao H; Okada K; Matsuo O; Collen D Thromb Haemost; 1991 Oct; 66(4):468-73. PubMed ID: 1796398 [TBL] [Abstract][Full Text] [Related]
11. Effects of fibrin and alpha2-antiplasmin on plasminogen activation by staphylokinase. Okada K; Ueshima S; Takaishi T; Yuasa H; Fukao H; Matsuo O Am J Hematol; 1996 Nov; 53(3):151-7. PubMed ID: 8895684 [TBL] [Abstract][Full Text] [Related]
12. Functional properties of p-anisoylated plasmin-staphylokinase complex. Lijnen HR; Van Hoef B; Smith RA; Collen D Thromb Haemost; 1993 Aug; 70(2):326-31. PubMed ID: 8236143 [TBL] [Abstract][Full Text] [Related]
17. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator. Aisina RB; Moukhametova LI; Varfolomeyev SD Biochemistry (Mosc); 2003 Nov; 68(11):1252-60. PubMed ID: 14640969 [TBL] [Abstract][Full Text] [Related]
18. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity. Hirata Y; Umemura K; Takiguchi Y; Uematsu T; Nakashima M Blood Coagul Fibrinolysis; 1993 Aug; 4(4):569-75. PubMed ID: 7692999 [TBL] [Abstract][Full Text] [Related]
19. Fibrinolysis--a review. Kane KK Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587 [TBL] [Abstract][Full Text] [Related]
20. Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis. Lijnen HR; Stassen JM; Collen D Thromb Haemost; 1995 May; 73(5):845-9. PubMed ID: 7482414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]